Literature DB >> 16628558

A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia.

Laura K Campbell1, Mary Scaduto, William Sharp, Lynette Dufton, Deborah Van Slyke, James A Whitlock, Bruce Compas.   

Abstract

BACKGROUND: Impaired neurocognitive functioning is one increasingly recognized long-term consequence of childhood ALL treatment. However, research findings have been inconsistent regarding the domains affected and the degree to which they are compromised. PROCEDURE: A comprehensive meta-analytic review of the long-term neurocognitive effects of childhood ALL was conducted. Studies were included if they were published in English, reported original quantitative data on the post-treatment neurocognitive functioning of childhood ALL patients in first remission and control groups, and used neurocognitive measures with adequate psychometric properties and published normative data.
RESULTS: Data from 28 empirical studies yielding 13 effect sizes across nine domains were extracted and analyzed. All effects were negative (g = -0.34 to -0.71), demonstrating that ALL survivors consistently experienced significant deficits in intellectual functioning, academic achievement, and specific neurocognitive abilities compared to control groups. The role of potential moderators, including treatment with cranial irradiation, age at time of diagnosis, and time since treatment ended, was examined. However, no effects emerged as clearly and consistently moderated by these variables.
CONCLUSIONS: The results from this meta-analysis suggest that declines in both global and specific areas of areas of neurocognitive functioning occur as a result of contemporary ALL treatment. Such deficits have significant implications for survivors' academic achievement and overall quality of life. Neurocognitive assessment plays a critical role in determining what remedial or specialized instruction is needed in childhood ALL survivors and should be included as a standard part of long-term follow-up care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16628558     DOI: 10.1002/pbc.20860

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  62 in total

1.  [Neurocognitive function of children with acute lymphoblastic leukemia and long-term disease-free survival and related influencing factors].

Authors:  Xiao-Yan Fu; Xiao-Tian Xie; Yan Zhao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  Mathematics intervention for prevention of neurocognitive deficits in childhood leukemia.

Authors:  Ida M Moore; Marilyn J Hockenberry; Cynthia Anhalt; Kathy McCarthy; Kevin R Krull
Journal:  Pediatr Blood Cancer       Date:  2011-09-21       Impact factor: 3.167

3.  Population-based exploration of academic achievement outcomes in pediatric acute lymphoblastic leukemia survivors.

Authors:  Lyndsay A Harshman; Sheila Barron; Anna M Button; Brian J Smith; Brian K Link; Charles F Lynch; Natalie L Denburg
Journal:  J Pediatr Psychol       Date:  2012-01-23

4.  The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment.

Authors:  Adrienne Viola; Lyn Balsamo; Joseph P Neglia; Pim Brouwers; Xiaomei Ma; Nina S Kadan-Lottick
Journal:  J Pediatr Hematol Oncol       Date:  2017-04       Impact factor: 1.289

5.  Declines Noted in Cognitive Processes and Association With Achievement Among Children With Leukemia.

Authors:  Kathleen C Insel; Marilyn J Hockenberry; Lynette L Harris; Kari M Koerner; Zhenqiang Lu; Kristin B Adkins; Olga A Taylor; Patricia M Gundy; Ida M Moore
Journal:  Oncol Nurs Forum       Date:  2017-07-01       Impact factor: 2.172

6.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

7.  Cognitive and attentional functioning in adolescents and young adults with Tetralogy of Fallot and d-transposition of the great arteries.

Authors:  Lexa K Murphy; Bruce E Compas; Kristen L Reeslund; Melissa C Gindville; May Ling Mah; Larry W Markham; Lori C Jordan
Journal:  Child Neuropsychol       Date:  2015-09-20       Impact factor: 2.500

8.  Statistical approaches to harmonize data on cognitive measures in systematic reviews are rarely reported.

Authors:  Lauren E Griffith; Edwin van den Heuvel; Isabel Fortier; Nazmul Sohel; Scott M Hofer; Hélène Payette; Christina Wolfson; Sylvie Belleville; Meghan Kenny; Dany Doiron; Parminder Raina
Journal:  J Clin Epidemiol       Date:  2014-12-08       Impact factor: 6.437

9.  Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses.

Authors:  Kristen E Robinson; Katherine L Livesay; Laura K Campbell; Mary Scaduto; Christopher J Cannistraci; Adam W Anderson; James A Whitlock; Bruce E Compas
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

10.  Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers.

Authors:  Wilburn E Reddick; Delaram J Taghipour; John O Glass; Jason Ashford; Xiaoping Xiong; Shengjie Wu; Melanie Bonner; Raja B Khan; Heather M Conklin
Journal:  Pediatr Blood Cancer       Date:  2014-01-25       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.